Core Viewpoint - The company anticipates a significant decline in net profit for the fiscal year 2025, projecting a profit of 8.05 million to 11.58 million yuan, which represents a decrease of 9.43 million to 12.96 million yuan compared to the previous year, equating to a year-on-year decline of 44.89% to 61.69% [1] Financial Performance - The expected net profit for 2025 is between 8.05 million and 11.58 million yuan [1] - This represents a decrease of 9.43 million to 12.96 million yuan compared to the previous year [1] - The projected decline in profit is between 44.89% and 61.69% year-on-year [1] Operational Changes - The company has experienced a phase change in its product sales structure, leading to a decline in overall gross profit margin [1] - Despite revenue growth, the company is facing profit decline due to high investments in marketing system construction, brand influence enhancement, product iteration, and new technology research and development [1] - Sales expenses, management expenses, and research and development expenses remain at a high level, contributing to the profit decline [1]

南财智讯1月29日电，澳华内镜发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为805 万元—1158万元，同比预减44.89%—61.69%；预计2025年全年归属于上市公司股东的扣除非经常性损 益的净利润为-1053万元—-700万元。本期业绩变化的主要原因：1、报告期内，公司海外市场准入及业 务拓展成效显著，海外销售额实现较快增长，此外新一代旗舰机型AQ400成功上市，进一步贡献业绩增 量，多因素共振下，公司整体收入较上年同期实现小幅稳步增长；2、报告期内，公司产品销售结构发 生阶段性变化，导致综合毛利率出现下滑，另一方面，公司为夯实长期竞争力，持续加大市场营销体系 建设、品牌影响力提升、产品迭代打磨及新技术研发的投入力度，销售费用、管理费用、研发费用仍保 持较高投入，导致业绩出现收入增长但利润下滑的情况；3、本报告期，公司预计非经常性损益影响归 属于上市公司股东的净利润约为1858万元，主要系公司本报告期获得的政府补助收益、理财收益等。上 年同期的非经常性损益金额为2729.84万元；4、上年同期财务数据比较基数较小，导致本期内相关比例 波动较大。 ...

Investment Rating - The report indicates a positive outlook for the medical equipment industry, with an expected year-on-year growth of 25% for the year 2025 [22]. Core Insights - The medical equipment industry is experiencing a slight decline in December data year-on-year, attributed to a high base effect from the previous year. However, there is a significant month-on-month increase of 38% due to accelerated budget spending at year-end [3]. - The report highlights that the current round of medical equipment upgrades is nearing its end, with expectations for a new round of equipment replacement in 2025, which is projected to be no less than the previous round [4]. - The report emphasizes the importance of government policies, including the issuance of long-term special bonds to support large-scale equipment upgrades and consumer replacement programs [15]. Summary by Relevant Sections Medical Imaging - December figures for medical imaging reached 9.8 billion yuan, a decrease of 11%, while the forecast for 2025 is 69.3 billion yuan, reflecting a growth of 37% [5]. Life Information and Support - In December, life information and support equipment generated 2.6 billion yuan, an increase of 8%, with a projected total of 16.7 billion yuan for 2025, marking a 28% growth [5]. Endoscopes - Soft endoscopes reported 1.1 billion yuan in December, down 9%, while hard endoscopes reached 1.2 billion yuan, down 7%. The 2025 projections for both are 7.8 billion yuan for soft endoscopes (+12%) and 7.8 billion yuan for hard endoscopes (+3%) [5]. Radiation Therapy - December figures for radiation therapy stood at 1.6 billion yuan, a slight increase of 1%, with a forecast of 9.6 billion yuan for 2025, indicating a growth of 32% [48]. Surgical Robots - Surgical robots saw a significant decline in December, with figures at 600 million yuan, down 24%, but are expected to reach 5.2 billion yuan in 2025, reflecting a robust growth of 54% [51]. Key Companies - Major companies in the sector include Mindray, which reported 1.9 billion yuan in December (+20%) and is projected to reach 11.2 billion yuan in 2025 (+35%), and United Imaging, with December figures of 2.2 billion yuan (0% change) and a forecast of 12.6 billion yuan (+37%) for 2025 [55][58].

截至9月30日，澳华内镜股东户数5549.00，较上期增加41.52%；人均流通股24268股，较上期减少 29.34%。2025年1月-9月，澳华内镜实现营业收入4.23亿元，同比减少15.57%；归母净利润-5609.25万 元，同比减少250.37%。 分红方面，澳华内镜A股上市后累计派现7628.41万元。近三年，累计派现5094.95万元。 机构持仓方面，截止2025年9月30日，澳华内镜十大流通股东中，富国精准医疗灵活配置混合A （005176）位居第三大流通股东，持股534.06万股，相比上期增加50.55万股。汇添富创新医药混合A （006113）位居第五大流通股东，持股358.52万股，相比上期减少31.33万股。汇添富医疗服务灵活配置 混合A（001417）位居第八大流通股东，持股204.51万股，相比上期减少24.36万股。工银前沿医疗股票 A（001717）、广发医疗保健股票A（004851）退出十大流通股东之列。 责任编辑：小浪快报 1月22日，澳华内镜跌1.57%，成交额4586.25万元。两融数据显示，当日澳华内镜获融资买入额440.37 万元，融资偿还320.75万元，融资净买 ...

（文章来源：证券日报） 证券日报网讯 1月16日，澳华内镜在互动平台回答投资者提问时表示，公司近年存在向欧盟成员国出口 及销售相关业务，多款核心产品已取得欧盟市场准入资质并实现销售；关于欧盟地区业务收入在公司整 体营业收入中的具体占比，请以公司对外披露信息为准；公司对欧盟市场的销售采用多元化模式推进， 一方面通过2018年收购的慕尼黑子公司WISAP开展当地的营销、销售及服务工作，另一方面也借助第 三方贸易商、代理商的渠道资源进行转销，以进一步拓宽市场覆盖范围，未来公司将持续深耕包括欧盟 在内的海外市场，相关业务进展敬请关注公司后续公开信息披露。 ...

Core Viewpoint - The medical equipment procurement scale is expected to grow rapidly year-on-year due to the implementation of the 2025 equipment renewal policy, with a significant increase in demand for high-end medical devices [1][2][3] Group 1: Equipment Procurement Trends - In December 2025, the procurement scale for new medical devices showed a decline in MR by 11.8%, CT by 7.3%, DR by 3.9%, and ultrasound by 1.3%, while endoscopes increased by 1.4% and surgical robots decreased by 23.9% [1][2] - Cumulatively for the year 2025, the procurement scale for MR increased by 31.4%, CT by 53.2%, DR by 53.2%, ultrasound by 42.3%, endoscopes by 16.3%, and surgical robots by 21.9% [2] Group 2: Company Performance - In December 2025, the performance of specific companies showed that Union Medical's MR declined by 17.4%, while its CT increased by 17.4%. Mindray's ultrasound grew by 13.8%, and KAILI's ultrasound decreased by 13.5%. KAILI's endoscope increased by 61.1%, and Aohua's endoscope grew by 9.4% [2] - For the entire year of 2025, Union Medical's MR grew by 15.6%, CT by 47.7%, Mindray's ultrasound by 56.3%, KAILI's ultrasound by 69.7%, KAILI's endoscope by 85.0%, and Aohua's endoscope by 24.4% [2] Group 3: Policy Impact - The 2024 policy aims to increase medical equipment investment by over 25% compared to 2023 by 2027, enhancing the configuration of high-end equipment to levels seen in middle-income countries [3] - The implementation of the equipment renewal policy is expected to significantly boost procurement levels across various medical institutions, leading to a recovery in the domestic market and a turning point for equipment companies [3]

（文章来源：证券日报） 证券日报网讯 1月8日，澳华内镜发布公告称，截至2026年1月7日，公司控股股东、实际控制人之一顾 小舟通过集中竞价及大宗交易合计减持260万股，占总股本1.93%，减持金额约1.16亿元，减持计划已实 施完毕，其持股比例降至14.21%。 ...

证券代码：688212 证券简称：澳华内镜 公告编号：2026-002 上海澳华内镜股份有限公司 控股股东、实际控制人减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 控股股东、实际控制人及其一致行动人持有的基本情况 本次减持计划实施前，顾康、顾小舟及其控制的上海小洲光电科技有限公司 （以下简称"小洲光电"）合计持有上海澳华内镜股份有限公司（以下简称"公 司"）40,569,960 股，占公司总股本的 30.13%。其中，小洲光电持有公司股份 1,879,260 股，占公司总股本的 1.40%；顾康持有公司股份 16,950,200 股，占公 司总股本的12.59%；顾小舟持有公司股份21,740,500股，占公司总股本的16.14%。 上述股份来源均为公司首次公开发行前取得的股份，且已于 2024 年 11 月 15 日 起上市流通。 减持计划的实施结果情况 公司于 2025 年 11 月 1 日在上海证券交易所网站（www.sse.com.cn）披露了 《控股股东、实际控制人 ...

澳华内镜公告，控股股东、实际控制人顾小舟已于2025年11月24日至2026年1月7日通过集中竞价减持 134.66万股、大宗交易减持125.34万股，合计减持260万股，减持比例1.93%，减持价格区间41.83～ 47.86元/股，套现1.16亿元；减持计划实施完毕，当前持股1914.05万股，占公司总股本14.21%。 ...

南财智讯1月8日电，澳华内镜公告，公司控股股东、实际控制人之一顾小舟及其一致行动人顾康、小洲 光电本次减持计划已实施完毕。截至2026年1月7日，顾小舟通过集中竞价交易方式累计减持公司股份 1,346,600股，占公司总股本的1.00%；通过大宗交易方式累计减持1,253,400股，占公司总股本的 0.93%，合计减持比例为1.93%。减持价格区间为41.83至47.86元/股，减持总金额为1.16亿元。本次减持 后，顾小舟持股比例由16.14%降至14.21%。 ...